New Cardiovascular Drugs Seem To Be Far Out Of Reach For Most American

There have been many new and approved medications designed to treat heart failure and cholesterol. These new medications have great expectations, but those expectations come along with a hefty price tag. While these medications might not be a fit for everyone, they may prove to be valuable, if they are effective in treating specific illnesses or controlling symptoms.

It is no secret that cardiovascular disease is the leading cause of death in men and women that live within the United States. Medical costs to treat these diseases are rapidly increasing as we speak. The medications account for a great deal of the costs, which is why it important to weigh the benefits and costs of each.

Heart failure is linked to insufficient oxygen enriched blood supply to the heart. If left untreated, it can lead to a heart attack or death, which is why pharmaceutical companies have worked diligently to develop medications that are effective in treating cardiovascular diseases. Corlanor is a cardiac drug that is prescribed to treat chronic heart failure and it is often used in conjunction with high doses of beta blockers. The individual’s resting pulse must average at least 70 BPM or more in order to be approved to take this drug.

Entresto is a combination drug that contains sacubitril and valsartan. This medication was designed to relax the blood vessels, which will improve the heart’s ability to pump blood in a more sufficient and efficient manner. The medication is expected to be a suitable replacement for many current cardiac medications that offer the same results. A wide clinical test was completed and the results were promising.

You should expect to pay around $375 a month or $12.50 a day, which is out of reach for most chronic heart failure victims.


New Cholesterol Medications

High cholesterol is linked to heart failure, which is why it is important to treat it properly. Praluent and Repatha are classed as PCSK9 inhibitors, but they are only available injection form. The physician or cardiologist will have to make the decision of whether or not the medications will help someone that suffers from uncontrollable hyperlipidemia or hypercholesterolemia (high cholesterol levels) and cannot take statins.

By taking these medications, it will allow a much larger amount of LDL (bad) cholesterol to be removed from the body in a much quicker manner. This is all made possible, by the medications ability to inactivate the PCSK9 protein found in the liver. These drugs will not be available for everyone, since they are so expensive. Praluent will cost around $1,120 every 28 days or $40 dollars a day and Repatha will cost $1,084 or $39 dollars a day.

While it is great to see the pharmaceutical companies focusing on developing drugs that are capable of treating chronic heart failure and hypercholesterolemia, it is a shame that the medication options are way out of reach for most Americans.